← Library
KPV (Lys-Pro-Val)
Research Use
Also known as α-MSH(11-13)
Function
Primary
IBD · Gut inflammation
Secondary
Wound healing · Antimicrobial
Mechanism
C-terminal tripeptide of α-MSH — activates MC1R/MC3R; reduces NF-κB activity; anti-inflammatory in intestinal epithelium; promotes wound closure.
Evidence
Pre-clinical / Observational
Research
Mouse colitis models; limited human data
Dosing
Range
300–500 mcg/day
Frequency
Once or twice daily
Route
Oral · Subcutaneous
Cycling
4–8 weeks on / 2–4 weeks off.
Benefits
- ·Anti-inflammatory in gut epithelium (preclinical)
- ·Wound healing support
- ·Low toxicity in animals
Risks
- ·Very limited human data
Contraindications
- ·Pregnancy
- ·Active malignancy (theoretical)
Regulatory
Not FDA-approved; research use
Functional Groups
Cited Works
- Luger TA et al. Anti-inflammatory potency of α-MSH/KPV. Ann N Y Acad Sci. 2003;994:133.source